46m
Why Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag For Obesity-MASH Drug - And What's Next
Altimmune recently received FDA Breakthrough Therapy Designation for its obesity and MASH drug candidate pemvidutide, based on mid-stage data showing meaningful MASH resolution and plans for a 52-week ...
Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven ...
Jacksonville Journal-Courier on MSN
Food companies are targeting users of weight-loss drugs with 'GLP-1 friendly' labels
Meals and snacks with "GLP-1 Friendly" labels on the packaging are becoming more common as a growing number of Americans try ...
As 25 pounds slid away, she felt less tired and found herself walking and biking more. Then her Medicare plan notified her it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results